Détail du document
Identifiant
doi:10.1186/s12916-021-02206-y...
Auteur
Theunissen, Frances Flynn, Loren L. Anderton, Ryan S. Akkari, P. AnthonyLangue
enEditeur
BioMed Central
Catégorie
Biomedicine, general
Année
2022
Date de référencement
10/02/2022
Mots clés
genetic marker structural variant amyotrophic lateral sclerosis clinical trials participant selection enrichment tool responder sub-population clinical markers trials alsRésumé
There is considerable variability in disease progression for patients with amyotrophic lateral sclerosis (ALS) including the age of disease onset, site of disease onset, and survival time.
There is growing evidence that short structural variations (SSVs) residing in frequently overlooked genomic regions can contribute to complex disease mechanisms and can explain, in part, the phenotypic variability in ALS patients.
Here, we discuss SSVs recently characterized by our laboratory and how these discoveries integrate into the current literature on ALS, particularly in the context of application to future clinical trials.
These markers may help to identify and differentiate patients for clinical trials that have a similar ALS disease mechanism(s), thereby reducing the impact of participant heterogeneity.
As evidence accumulates for the genetic markers discovered in SQSTM1 , SCAF4 , and STMN2 , we hope to improve the outcomes of future ALS clinical trials.
Theunissen, Frances,Flynn, Loren L.,Anderton, Ryan S.,Akkari, P. Anthony, 2022, Short structural variants as informative genetic markers for ALS disease risk and progression, BioMed Central
